SkinBioTherapeutics slumps most since 2020 on profit warning amid probe against former CEO

Skinbiotherapeutics

16/02/2026 09:12

** Shares of SkinBioTherapeutics SBTX.L crumble 39% to 7.5p , set for the biggest single-day pct drop since April 2020

** British skin-health co SBTX investigates former CEO Stuart Ashman & believes he misrepresented material financial information to board & auditors

        ** Adds, resulting restatement of 2025 accounts means fiscal 2026 results would be "significantly below" market expectations

** Alleges Ashman had misrepresented material information, which would require reversing about 770,000 pounds ($1.05 mln )in royalty income from fiscal 2025 accounts

** In 2025, stock fell ~15%

 (Reporting by Ankita Bora in Bengaluru)

 ((Ankita.Bora@thomsonreuters.com))